Cantor Fitzgerald Forecasts Cytokinetics FY2026 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Equities research analysts at Cantor Fitzgerald decreased their FY2026 earnings estimates for Cytokinetics in a research note issued on Thursday, November 6th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will earn ($6.56) per share for the year, down from their previous forecast of ($6.39). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, topping the consensus estimate of ($1.59) by $0.05. The company had revenue of $1.94 million for the quarter, compared to the consensus estimate of $6.05 million. During the same period in the previous year, the firm posted ($1.36) EPS. The business’s quarterly revenue was up 318.1% on a year-over-year basis.

A number of other equities analysts have also weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $120.00 target price on shares of Cytokinetics in a research note on Monday, September 29th. Raymond James Financial started coverage on Cytokinetics in a report on Wednesday, July 30th. They issued a “market perform” rating on the stock. Bank of America increased their price objective on Cytokinetics from $52.00 to $56.00 and gave the stock a “neutral” rating in a research report on Thursday, October 2nd. Needham & Company LLC reissued a “buy” rating and issued a $72.00 target price on shares of Cytokinetics in a research report on Tuesday, September 2nd. Finally, Barclays upped their price target on shares of Cytokinetics from $71.00 to $82.00 and gave the company an “overweight” rating in a research note on Monday, October 6th. Thirteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $76.64.

Cytokinetics Stock Down 0.2%

Shares of CYTK stock opened at $60.16 on Monday. Cytokinetics has a 12-month low of $29.31 and a 12-month high of $64.13. The company has a market capitalization of $7.36 billion, a PE ratio of -11.80 and a beta of 0.58. The firm has a 50 day moving average price of $55.26 and a two-hundred day moving average price of $42.13.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its position in Cytokinetics by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 2,994,445 shares of the biopharmaceutical company’s stock worth $98,948,000 after purchasing an additional 56,961 shares during the period. Vestal Point Capital LP grew its holdings in shares of Cytokinetics by 14.8% in the second quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company’s stock worth $98,294,000 after acquiring an additional 384,469 shares during the period. Westfield Capital Management Co. LP increased its position in Cytokinetics by 2.4% during the first quarter. Westfield Capital Management Co. LP now owns 1,310,336 shares of the biopharmaceutical company’s stock valued at $52,662,000 after acquiring an additional 30,346 shares during the last quarter. Norges Bank purchased a new stake in Cytokinetics during the second quarter valued at $39,122,000. Finally, Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. lifted its holdings in Cytokinetics by 571.2% in the second quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 1,082,563 shares of the biopharmaceutical company’s stock valued at $35,768,000 after acquiring an additional 921,278 shares during the period.

Insiders Place Their Bets

In other news, Director Wendell Wierenga sold 4,375 shares of the business’s stock in a transaction on Monday, October 27th. The stock was sold at an average price of $58.68, for a total value of $256,725.00. Following the completion of the transaction, the director owned 32,444 shares in the company, valued at $1,903,813.92. The trade was a 11.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert I. Blum sold 5,000 shares of the company’s stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $62.86, for a total value of $314,300.00. Following the transaction, the chief executive officer directly owned 358,108 shares in the company, valued at approximately $22,510,668.88. The trade was a 1.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 56,983 shares of company stock valued at $3,165,356. 2.70% of the stock is currently owned by company insiders.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.